Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), that is not well controlled despite treatment with topical prescription therapies.

Lebrikizumab has received approval in the European Union and Japan, marketed under the brand name EBGLYSS. Lilly says it remains committed to launching lebrikizumab in the U.S., as a potential first-line biologic treatment following topical prescription therapies. 

Additionally, in the coming months, Lilly will initiate Phase 3 studies evaluating lebrikizumab in two new indications—chronic rhinosinusitis with nasal polyps and allergic rhinitis due to perennial allergens. Lebrikizumab will be the first biologic to be evaluated in Phase 3 for perennial allergic rhinitis.